Histone deacetylase inhibitors and cancer therapy

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 64-67

  La Thangue, N B ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b BioAlliance Pharma   (France)

Author keywords

Cancer therapy; Histone deacetylase inhibitors

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; ANTINEOPLASTIC AGENT; APIDICIN; BUTYRIC ACID; CCI 994; FR 901228; HISTONE DEACETYLASE INHIBITOR; IMATINIB; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PIVALOYLOXYMETHYL BUTYRATE; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; DNA REPAIR; DNA SYNTHESIS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; EPIGENETICS; HUMAN; IC 50; PHARMACODYNAMICS; PROTEIN EXPRESSION; PROTEIN METABOLISM; T CELL LYMPHOMA; TRANSCRIPTION REGULATION;

EID: 11244316375     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.64     Document Type: Conference Paper

References (17)

1. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074-1080.
2. De Ruijter AJM, van Gennip AH, Caron HN, Kemp S, van Kuilenburg ABP. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370:737-749.
3. Cheng HL, Mostoslavsky R, Saito S et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci 2003; 100:10794-10799.
4. Kelly WK, Richon VM, O'Connor O et al. Phase I clinical trial of histone deacetylase inhibitors: suberoylanilide hydroxamic acid administered intravenously. Clin Can Res 2003; 9:3578-3588.
5. Blaheta RA, Nau H, Michaelis M, Cinatlt Jr J. Valproate and valproate-analogues: potent tools to fight against cancer. Curr Med Chem 2002; 9:1417-1433.
6. Sandor V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002; 8:718-728.
7. Saito A, Yamashita T, Mariko Y et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumors. Proc Natl Acad Sci 1999; 96:4592-4597.
8. Prakash S, Foster BJ, Meyer M et al. Chronic oral administration of CI-994. Invest New Drugs 2001; 19:1-11.
9. McLaughlin F, Finn P, La Thangue NB. The cell cycle, chromatin and cancer: mechanism based therapeutics come of age. Drug Disc Today 2003; 8:793-802.
10. Chan HM, La Thangue NB. p300/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci 2001; 11:2363-2373.
11. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2:151-163.
12. Yu C, Rahmani M, Almerara J, et al. Histone deacetylase inhibitors promote ST1571-mediated apoptosis in ST1571-sensitive and -resistant Bcr/Abl+ Human Myeloid leukaemia cells. Cancer Res 2003; 63:2118-2126.
13. Nimmanapalli R, Fuino L, Stobaugh C, Richon VM, Bhalla K. Co-treatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances Gleevec-induced apoptosis of Bcr-Abl positive human acute leukemia cells. Blood 2003; 101:3236-3239.
14. Jang ER, Lim S-J, Lee ES, et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 2004; 23:1724-1736.
15. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anti-Canc Agents 2003; 3:187-199.
16. Hu E, Dul E, Sung CM et al. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003; 2:720-728.
17. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res 2002; 62:4616-4621.